Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements.
Net profit68.75 millionEGP · +18.3% vs the same period a year earlier
Total assets913 millionEGP · +21.1% vs the same period a year earlier
Shareholders' equity465 millionEGP · +11.1% vs the same period a year earlier
Operating cash flow-77.33 millionEGP · −2936.5% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q3 2023 was about 68.75 million EGP, up +18.3% from 58.1 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 913 million EGP, and shareholders' equity about 465 million EGP.
- Operating cash flow for Q3 2023 was negative at 77.33 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit68.75 million58.1 million+18.3%
Gross profit189 million173 million+9.5%
Total assets913 million754 million+21.1%
Total liabilities448 million336 million+33.5%
Shareholders' equity465 million419 million+11.1%
Total liabilities and equity913 million754 million+21.1%
Operating cash flow-77.33 million2.73 million−2936.5%
Investing cash flow-791 thousand-1.75 million+54.9%
Financing cash flow-9.88 million-15.28 million+35.3%
Net change in cash-88 million-14.3 million−515.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy